All In Biotech

Drug Trial Radar · NCT05463263

A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

An Open-Label, First in Human, Phase 1/2 to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of the CTPS1 Inhibitor STP938 In Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

Last checked: Nov 19, 2026Latest source record: Jun 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Aug 3, 2022

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Step Pharma, SASIndustry
Sponsor type
Industry
First posted
Jul 18, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Phase 1 part of the study is a dose escalation of STP938 as monotherapy. The Phase 2 part of the study is cohort expansion of STP938 as a monotherapy in 5 different B and T cell lymphomas.

Conditions

  • Lymphoma, B-Cell
  • Lymphoma, T-Cell

Interventions

  • STP938Drug

    Small molecule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Tolerability (Phase 1 / Dose Escalation)Time frame: Through study completion, an average of 9 months
  2. Objective Response Rate (ORR) (Phase 2 / Dose Expansion)Time frame: Through study completion, an average of 9 months

Locations

15 sites in 3 countries. Site status is shown where the registry gives one.

  • Colorado Blood Cancer Institute

    Denver, Colorado · Recruiting

  • Florida Cancer Specialists

    Sarasota, Florida · Recruiting

  • Memorial Sloan Kettering

    New York, New York · Recruiting

  • The Centre Léon Bérard

    Lyon, France · Recruiting

  • Institut Paoli Calmettes

    Marseille, France · Recruiting

  • CHU de Nantes

    Nantes, France · Recruiting

  • Institut Gustave Roussy

    Villejuif, France · Recruiting

  • Hôpital Saint-Louis

    Paris, Paris, France · Recruiting

  • University Hospitals of Leicester NHS Trust

    Leicester, United Kingdom · Recruiting

  • Imperial College / Clinical Trials Unit, Hammersmith Hospital

    London, United Kingdom · Recruiting

  • The Christie

    Manchester, United Kingdom · Recruiting

  • Nottingham City Hospital

    Nottingham, United Kingdom · Recruiting

  • Churchill Hospital

    Oxford, United Kingdom · Recruiting

  • Derriford Hospital

    Plymouth, United Kingdom · Recruiting

  • The Royal Marsden

    Sutton, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.